Skip to content

Clinical trials

Phase 3 Lung Diseases trials in Australia

Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.

Filters: Condition: Lung Diseases Phase: Phase 3 Country / region: Australia Clear all

18 trials match Source: ClinicalTrials.gov registrations

Trials started per year

By phase, 2000 to 2026.

Trials started per year
CategoryTrials
20071
20092
20131
20142
20162
20193
20201
20221
20231
20243
20251

Status

Trials by registry status. Select a bar to filter.

Trials by status
CategoryTrials
Completed9
Recruiting5
Terminated2
Active, not recruiting1
Enrolling by invitation1

Top lead sponsors

A sponsor with a page on Pharma Observatory links to it.

Top lead sponsors
CategoryTrials
AstraZeneca6
United Therapeutics2
Vertex Pharmaceuticals Incorporated2
Eli Lilly and Company1
GlaxoSmithKline1
Hoffmann-La Roche1
Mannkind Corporation1
Mercy Hospital for Women, Australia1
Nuvalent Inc.1
Seagen, a wholly owned subsidiary of Pfizer1

Top conditions

MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.

Top conditions
CategoryTrials
Lung Diseases18
Respiratory Tract Diseases12
Bronchial Diseases5
Carcinoma, Non-Small-Cell Lung4
Lung Diseases, Obstructive4
Lung Neoplasms4
Asthma3
Connective Tissue Diseases3
Pathologic Processes3
Respiratory Tract Infections3

Trials

Showing 1 to 18 of 18. Each trial links to its page on Pharma Observatory.

Recently changed trials

Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.

No changes to these trials in the last 7 days.

Go deeper on Pharma Observatory

Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.